EA200702190A1 - Вакцинная композиция - Google Patents

Вакцинная композиция

Info

Publication number
EA200702190A1
EA200702190A1 EA200702190A EA200702190A EA200702190A1 EA 200702190 A1 EA200702190 A1 EA 200702190A1 EA 200702190 A EA200702190 A EA 200702190A EA 200702190 A EA200702190 A EA 200702190A EA 200702190 A1 EA200702190 A1 EA 200702190A1
Authority
EA
Eurasian Patent Office
Prior art keywords
adenoviruses
relates
hiv
vectors
viral vectors
Prior art date
Application number
EA200702190A
Other languages
English (en)
Inventor
Питер Франц Эртл
Джон Филип Тайт
Кэтрин Энн Ван Уэли
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200702190(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA200702190A1 publication Critical patent/EA200702190A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к вирусным векторам, содержащим олигонуклеотиды, кодирующие полипептиды вируса иммунодефицита человека (HIV), более конкретно, где вирусный вектор представляет собой аденовирус. В частности, такие аденовирусы представляют собой аденовирусы приматов, отличных от человека, такие как аденовирусы обезьян, более конкретно аденовирусы шимпанзе. В частности, изобретение относится к аденовирусным векторам, которые содержат полинуклеотидные последовательности HIV, которые кодируют множество различных антигенов HIV, например два, или три, или более антигенов HIV. Изобретение также относится к способам получения вирусных векторов, к вирусным векторам, получаемым этими способами, и к применению векторов в медицине, в особенности профилактической или терапевтической вакцинации.
EA200702190A 2005-05-12 2006-05-10 Вакцинная композиция EA200702190A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68038905P 2005-05-12 2005-05-12
PCT/EP2006/004854 WO2006120034A1 (en) 2005-05-12 2006-05-10 Vaccine composition

Publications (1)

Publication Number Publication Date
EA200702190A1 true EA200702190A1 (ru) 2008-04-28

Family

ID=36954770

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702190A EA200702190A1 (ru) 2005-05-12 2006-05-10 Вакцинная композиция

Country Status (20)

Country Link
US (1) US20090208515A1 (ru)
EP (1) EP1880012B1 (ru)
JP (2) JP5175178B2 (ru)
KR (1) KR101451620B1 (ru)
CN (2) CN101384722A (ru)
AR (1) AR053275A1 (ru)
AU (1) AU2006245920A1 (ru)
BR (1) BRPI0608798A2 (ru)
CA (1) CA2608316A1 (ru)
EA (1) EA200702190A1 (ru)
ES (1) ES2546330T3 (ru)
IL (1) IL186828A (ru)
MA (1) MA29458B1 (ru)
MX (1) MX2007014038A (ru)
NO (1) NO20075648L (ru)
PE (1) PE20061372A1 (ru)
SG (1) SG182173A1 (ru)
TW (1) TW200716750A (ru)
WO (1) WO2006120034A1 (ru)
ZA (1) ZA200709518B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ550416A (en) 2001-11-21 2008-06-30 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US20090246220A1 (en) 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
SI2137210T1 (sl) * 2007-03-02 2017-01-31 Glaxosmithkline Biologicals S.A. Nov postopek in sestavki
BRPI0822651A2 (pt) * 2007-11-28 2014-10-14 Univ Pennsylvania Subfamília b de adenovírus sadv-28, -27, 29, -32, -33 e -35 de símio e seus usos
CN101883858B (zh) * 2007-11-28 2015-07-22 宾夕法尼亚大学托管会 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
CN102016011B (zh) 2008-03-04 2013-12-11 宾夕法尼亚大学托管会 猿猴腺病毒sadv-36、-42.1、-42.2和-44及其应用
CN105709221B (zh) 2011-04-06 2020-11-17 拜欧瓦克西姆有限公司 用于预防和/或治疗人中的hiv疾病的药物组合物
AU2013231423B2 (en) 2012-03-12 2018-10-04 Janssen Vaccines & Prevention B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
AU2013262626B2 (en) 2012-05-18 2018-11-29 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1302, A1320, A1331 and A1337 and uses thereof
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
SG10201804469RA (en) * 2013-03-14 2018-06-28 Amgen Inc Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
WO2016146844A1 (en) 2015-03-18 2016-09-22 Janssen Vaccines & Prevention B.V. Assays for recombinant expression systems
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
CN107921118B (zh) * 2015-06-12 2022-11-08 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
US10343884B2 (en) 2015-07-10 2019-07-09 E. & J. Gallo Winery System and method for dispensing a beverage
CA3023322A1 (en) 2016-05-12 2017-11-16 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
BR112018075969A2 (pt) 2016-06-20 2019-04-02 Janssen Vaccines & Prevention B.V. promotor bidirecional potente e equilibrado
EP3490610A4 (en) 2016-08-01 2020-05-20 The Wistar Institute Of Anatomy And Biology DEFICIENTLY REPLICABLE ADENOVIRAL VECTOR COMPOSITIONS AND METHODS FOR VACCINE APPLICATIONS
CN110268061A (zh) 2017-02-09 2019-09-20 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4255397A (en) * 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
WO2002022080A2 (en) * 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US20040241181A1 (en) * 2001-06-22 2004-12-02 Ertl Hildeghund C. J. Methods of inducing a cytotoxic immune response and recormbinant simian adenovirus compositions useful therein
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB2406336A (en) * 2003-09-24 2005-03-30 Oxxon Pharmaccines Ltd HIV Pharmaccines
CA2539864A1 (en) * 2003-09-24 2005-04-07 Oxxon Therapeutics Limited Hiv pharmaccines
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
MX2007014038A (es) 2008-02-11
KR101451620B1 (ko) 2014-10-21
AR053275A1 (es) 2007-04-25
KR20080021659A (ko) 2008-03-07
CA2608316A1 (en) 2006-11-16
AU2006245920A1 (en) 2006-11-16
SG182173A1 (en) 2012-07-30
ZA200709518B (en) 2014-01-29
MA29458B1 (fr) 2008-05-02
PE20061372A1 (es) 2007-01-16
EP1880012B1 (en) 2015-07-08
CN101384722A (zh) 2009-03-11
IL186828A0 (en) 2008-02-09
JP2013046613A (ja) 2013-03-07
ES2546330T3 (es) 2015-09-22
NO20075648L (no) 2008-02-07
IL186828A (en) 2015-06-30
EP1880012A1 (en) 2008-01-23
JP2008539746A (ja) 2008-11-20
US20090208515A1 (en) 2009-08-20
WO2006120034A8 (en) 2007-11-15
BRPI0608798A2 (pt) 2011-03-15
CN103088060A (zh) 2013-05-08
JP5175178B2 (ja) 2013-04-03
WO2006120034A1 (en) 2006-11-16
TW200716750A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
EA200702190A1 (ru) Вакцинная композиция
NO20090194L (no) Rekombinant viral vaksine
MX2020000221A (es) Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas.
RU2015135890A (ru) Композиция вакцины
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
JP2016501015A5 (ja) デングウイルス血清型４（ｄｅｎ−４）構築物に関する組成物、方法および使用
MX2018007234A (es) Vectores virales adenoasociados utiles en el tratamiento de atrofia muscular espinal.
JP2008508859A5 (ru)
CY1106334T1 (el) Βελτιστοποιημενου κωδικονιου αλληλουχιες ιου θηλωματος
NZ708144A (en) Recombinant adenoviruses and use thereof
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
JP2014534202A5 (ru)
MX340880B (es) Vacunas mejoradas y metodos para uso de las mismas.
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
MX2021005345A (es) Composiciones y metodos.
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
EA202091516A1 (ru) Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
TW200502246A (en) Vaccine
WO2008115314A3 (en) Flavivirus vaccine vector against influenza virus
WO2003076591A3 (en) Compositions and methods for generating an immune response
EA201990719A1 (ru) Новые промоторы
ATE473756T1 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs
DE602004027362D1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320